US EditioniOnctura doses first subject in Phase II uveal melanoma treatment trial
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
iOnctura doses first subject in Phase II uveal melanoma treatment trial
iOnctura has dosed the first subject in the Phase II OCULE-01 trial of oral roginolisib in individuals with metastatic uveal melanoma (UM).The post iOnctura doses first subject in Phase II uveal melanoma treatment trial appeared first on Clinical Trials Arena.
iOnctura commences randomized Phase II study in metastatic uveal melanoma – Optimum Strategic Communications
First patient dosed in Phase II OCULE-01 study with roginolisib, an allosteric modulator of PI3Kδ The European Medicines Agency (EMA) has granted Orphan Drug Designation for roginolisib for treatment of uveal melanoma – benefits include 10 years market exclusivity in the European Union Geneva, Switzerland and Amsterdam, The Netherlands, 20 March 2025 – iOnctura, a […]
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
